Working… Menu

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04037566
Recruitment Status : Recruiting
First Posted : July 30, 2019
Last Update Posted : July 30, 2019
Xi'An Yufan Biotechnology Co.,Ltd
Information provided by (Responsible Party):
Gao Guangxun, Xijing Hospital

Brief Summary:
This is a first-in-human trial proposed to test CD19-specific CAR-T cells with edited endogenous HPK1 (XYF19 CAR-T cells) in patients with relapsed or refractory CD19+ leukemia or lymphoma. This is an investigational study designed as a single-center, open-label and single-arm clinical trial.

Condition or disease Intervention/treatment Phase
Leukemia Lymphocytic Acute (ALL) in Relapse Leukemia Lymphocytic Acute (All) Refractory Lymphoma, B-Cell CD19 Positive Genetic: XYF19 CAR-T cell Drug: Cyclophosphamide Drug: Fludarabine Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia Lymphoma

Arm Intervention/treatment
Experimental: XYF19 CAR-T cell
One arm study consisting of "3 + 3" dose escalation study design followed by dose expansion phase at determined MTD.
Genetic: XYF19 CAR-T cell
Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.

Drug: Cyclophosphamide
A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.

Drug: Fludarabine
A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.

Primary Outcome Measures :
  1. The adverse events associated with XYF19 CAR-T cells product will be assessed. [ Time Frame: 30 days ]
    Determine safety profile of a single infusion of XYF19 CAR-T cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Occurrence of study related adverse events defined as NCI CTCAE v5.0 > grade 3 possibly, probably, or definitely related to study treatment. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to adverse event.

  2. Maximum tolerated dose (MTD) as determined by dose limiting toxicity (DLT). [ Time Frame: 30 days ]
    The MTD is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT). The dose limiting toxicity is defined as CTCAE grades non-reversible grade 3, or any grade 4-5 allergic reactions related to the study cell infusion; CTCAE grades non-reversible grade 3, or any grade 4-5 autoimmune reactions related to the study cell infusion; or CTCAE grades non-reversible non-hematologic grade 3, or any grade 4-5 organ toxicity (cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic) not pre-existing or due to the underlying malignancy and occurring within 30 days of study product infusion related to study cell infusion. The study will employ a standard 3+3 design to find the MTD of XYF19 CAR-T cells dose.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must meet all the following criteria to be selected:

    1. Willing to provide consent/assent for participation in the study by patient or his/her legal guardian;
    2. Male or Female subjects age ≥18 and ≤55 years;
    3. Evidence of relapsed/refractory CD19+ B cell hematological malignancies. The most common relapsed/refractory B cell hematological malignancies include: (1) B cell acute lymphoblastic leukemia (B-ALL); (2) B cell lymphomas, including indolent B cell lymphoma (CLL, FL, MZL, LPL, HCL) and aggressive B cell lymphoma (DLBCL, BL, MCL);
    4. Subjects (20 subjects of B cell acute lymphoblastic leukemia and 20 subjects of B cell lymphoma) with the following conditions:

      1. Failure to achieve complete remission (CR) after at least two lines of standard chemotherapy while not suitable for HSCT (auto/allo-HSCT);
      2. Relapse after CR, but not eligible for HSCT (auto/allo-HSCT);
      3. Failure to achieve remission or relapse after HSCT;
    5. Leukemia patient confirmed by bone marrow aspiration that has not been alleviated; lymphoma patient with measurable or assessable lesions;
    6. Adequate organ function:

      1. Liver: ALT/AST ≥ 3 × ULN, total bilirubin ≤34.2 mol/L;
      2. Kidney: Creatinine<220 µmol/L, creatinine clearance rate (CCR) ≥ 60 mL/min;
      3. Lung: arterial oxygen saturation ≥95%;
      4. Heart: Left ventricular ejection fraction (LVEF) ≥40%;
      5. Absolute lymphocyte count (ALC) ≥ 100/μL, absolute neutrophil count (ANC) ≥ 1,000/μL, platelets (PLT) ≥ 75,000/μL;
    7. No prior anti-cancer therapy, including chemotherapy, radiotherapy, immunotherapy (immunosuppression) within 4 weeks prior to enrollment, and toxic reactions of all prior treatments recovered to grade ≤1 at the time of enrollment (except for low toxicity such as alopecia);
    8. Presence of smooth peripheral superficial venous blood flow to fulfill intravenous infusion;
    9. Karnofsky performance score ≥60; ECOG ≤2; estimated survival ≥3 months.

Exclusion Criteria:

  • Subjects meeting one or more of the following criteria will be excluded:

    1. Female patient who is pregnant or breastfeeding ;
    2. Male or Female patient within Pregnancy Program in 1 year;
    3. Unwilling or unable to guarantee effective contraceptive measures (condoms or contraceptives) within 1 year after enrollment;
    4. Presence of uncontrolled infectious disease within 4 weeks prior to enrollment:
    5. Active hepatitis B or hepatitis C infection;
    6. HIV infection;
    7. Active TB;
    8. Presence of active malignancy other than disease under study, confirmed by pathology;
    9. Severe autoimmune diseases or immunodeficiency;
    10. Suffering from allergies;
    11. Joining another clinical trial within 6 weeks prior to enrollment;
    12. Using systemic corticosteroid within 4 weeks prior to enrollment (except for those who use inhaled steroids);
    13. Psychiatric disorders;
    14. History of epilepsy and seizures or other CNS pathology;
    15. Addiction to or abuse of drugs;
    16. Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04037566

Layout table for location contacts
Contact: Guangxun GAO, Dr. +86 29 84775203
Contact: Yu WANG, Dr. +86 29 88764122

Layout table for location information
China, Shannxi
Xijing Hospital Recruiting
Xi'an, Shannxi, China, 710032
Contact: Guangxun GAO, Dr.    +86 29 84775203   
Contact: Yu WANG, Dr.    +86 29 88764122   
Sponsors and Collaborators
Xijing Hospital
Xi'An Yufan Biotechnology Co.,Ltd
Layout table for investigator information
Principal Investigator: Guangxun GAO, Dr. Xijing Hospital
Layout table for additonal information
Responsible Party: Gao Guangxun, Director of Hematology Department, Xijing Hospital Identifier: NCT04037566    
Other Study ID Numbers: V2.1
First Posted: July 30, 2019    Key Record Dates
Last Update Posted: July 30, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gao Guangxun, Xijing Hospital:
Leukemia Lymphocytic Acute
Lymphoma, B-Cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists